Targets › TTR
10 programs from 8 companies in 17 trials: 10 Phase 3, 3 Phase 2, 3 Phase 4, 1 Phase 1; Cardiovascular, Neurology; next expected readout Jan 2027.
Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain. (UniProt, P02766)
Open in Phaseline: the race on TTR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Qilu Pharmaceutical | Tafamidis Transthyretin stabiliser | TTR | Phase 4 | Transthyretin Amyloid Polyneuropathy; Transthyretin Cardiac Amyloidosis | Jan 2028 |
| Eidos Therapeutics, a BridgeBio company | Acoramidis Transthyretin stabiliser | TTR | Phase 4 | Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM); Amyloid Cardiomyopathy, Transthyretin-Related; Amyloidosis; Amyloid Cardiomyopathy | Apr 2028 |
| AstraZeneca | Eplontersen Transthyretin mRNA antisense inhibitor | TTR | Phase 3 | Transthyretin Amyloid Cardiomyopathy; Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Jan 2027 |
| Alnylam Pharmaceuticals | Vutrisiran Transthyretin mRNA rnai inhibitor | TTR | Phase 3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Jan 2027 |
| Intellia Therapeutics | nexiguran ziclumeran (NTLA-2001) in vivo CRISPR/Cas9 gene editing targeting TTR gene | TTR | Phase 3 | Neuromuscular Disease; Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Jul 2027 |
| AstraZeneca | ALXN2220 anti-TTR monoclonal antibody | TTR | Phase 3 | Transthyretin Amyloid Cardiomyopathy | Dec 2027 |
| Alnylam Pharmaceuticals | Nucresiran (ALN-TTRSC04) TTR synthesis inhibitor; siRNA targeting TTR mRNA | TTR | Phase 3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; Transthyretin Amyloidosis With Cardiomyopathy | Dec 2027 |
| Ionis Pharmaceuticals | Eplontersen Transthyretin mRNA antisense inhibitor | TTR | Phase 3 | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | Aug 2029 |
| Neurimmune | ALXN2220 anti-transthyretin (TTR) monoclonal antibody | TTR | Phase 2 | Amyloid Transthyretin Cardiomyopathy | – |
| Novo Nordisk | Coramitug Anti-transthyretin (TTR) monoclonal antibody; promotes removal of TTR amyloid deposits and | TTR | Phase 1 | Transthyretin Amyloid Cardiomyopathy | May 2027 |
Transthyretin Amyloid Cardiomyopathy (3) Transthyretin Amyloidosis (ATTR) With Cardiomyopathy (2) Amyloid Transthyretin Cardiomyopathy (1) Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (1) Transthyretin Amyloidosis With Cardiomyopathy (1) Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (1) Neuromuscular Disease (1) Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) (1) Amyloid Cardiomyopathy, Transthyretin-Related (1) Amyloidosis (1) Amyloid Cardiomyopathy (1) Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (1)
small molecule (4), other (4), antibody (1), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.